Women Infertility – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Women Infertility – Pipeline Review, H2 2017’, provides an overview of the Women Infertility pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Women Infertility, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Women Infertility

The report reviews pipeline therapeutics for Women Infertility by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Women Infertility therapeutics and enlists all their major and minor projects

The report assesses Women Infertility therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Women Infertility

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Women Infertility

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P Therapeutics LLC

AbbVie Inc

Addex Therapeutics Ltd

APAvadis Biotechnologies Srl

ASKA Pharmaceutical Co Ltd

Astellas Pharma Inc

Bayer AG

Cadila Healthcare Ltd

Dong-A Socio Holdings Co Ltd

ElexoPharm GmbH

EndoCeutics Inc

Enteris BioPharma Inc

Evotec AG

Ferring International Center SA

Forendo Pharma Ltd

Glycotope GmbH

Isifer AB

Kissei Pharmaceutical Co Ltd

Lipicard Technologies Ltd

Livzon Pharmaceutical Group Inc

Luye Pharma Group Ltd

Myovant Sciences Ltd

Navya Biologicals Pvt Ltd

Nippon Shinyaku Co Ltd

Nora Therapeutics Inc

ObsEva SA

Ogeda SA

Pangen Biotech Inc.

Pantec Biosolutions AG

Philogen SpA

Repros Therapeutics Inc

Richter Gedeon Nyrt

SK Chemicals Co Ltd

Takeda Pharmaceutical Co Ltd

ValiRx Plc

Viramal Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 4

Women Infertility - Overview 5

Women Infertility - Therapeutics Development 6

Women Infertility - Therapeutics Assessment 18

Women Infertility - Companies Involved in Therapeutics Development 28

Women Infertility - Drug Profiles 45

Women Infertility - Dormant Projects 161

Women Infertility - Discontinued Products 164

Women Infertility - Product Development Milestones 165

Appendix 177

List of Tables

List of Tables

Number of Products under Development for Women Infertility, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Women Infertility – Pipeline by 4P Therapeutics LLC, H2 2017

Women Infertility – Pipeline by AbbVie Inc, H2 2017

Women Infertility – Pipeline by Addex Therapeutics Ltd, H2 2017

Women Infertility – Pipeline by APAvadis Biotechnologies Srl, H2 2017

Women Infertility – Pipeline by ASKA Pharmaceutical Co Ltd, H2 2017

Women Infertility – Pipeline by Astellas Pharma Inc, H2 2017

Women Infertility – Pipeline by Bayer AG, H2 2017

Women Infertility – Pipeline by Cadila Healthcare Ltd, H2 2017

Women Infertility – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Women Infertility – Pipeline by ElexoPharm GmbH, H2 2017

Women Infertility – Pipeline by EndoCeutics Inc, H2 2017

Women Infertility – Pipeline by Enteris BioPharma Inc, H2 2017

Women Infertility – Pipeline by Evotec AG, H2 2017

Women Infertility – Pipeline by Ferring International Center SA, H2 2017

Women Infertility – Pipeline by Forendo Pharma Ltd, H2 2017

Women Infertility – Pipeline by Glycotope GmbH, H2 2017

Women Infertility – Pipeline by Isifer AB, H2 2017

Women Infertility – Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017

Women Infertility – Pipeline by Lipicard Technologies Ltd, H2 2017

Women Infertility – Pipeline by Livzon Pharmaceutical Group Inc, H2 2017

Women Infertility – Pipeline by Luye Pharma Group Ltd, H2 2017

Women Infertility – Pipeline by Myovant Sciences Ltd, H2 2017

Women Infertility – Pipeline by Navya Biologicals Pvt Ltd, H2 2017

Women Infertility – Pipeline by Nippon Shinyaku Co Ltd, H2 2017

Women Infertility – Pipeline by Nora Therapeutics Inc, H2 2017

Women Infertility – Pipeline by ObsEva SA, H2 2017

Women Infertility – Pipeline by Ogeda SA, H2 2017

Women Infertility – Pipeline by Pangen Biotech Inc., H2 2017

Women Infertility – Pipeline by Pantec Biosolutions AG, H2 2017

Women Infertility – Pipeline by Philogen SpA, H2 2017

Women Infertility – Pipeline by Repros Therapeutics Inc, H2 2017

Women Infertility – Pipeline by Richter Gedeon Nyrt, H2 2017

Women Infertility – Pipeline by SK Chemicals Co Ltd, H2 2017

Women Infertility – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017

Women Infertility – Pipeline by ValiRx Plc, H2 2017

Women Infertility – Pipeline by Viramal Ltd, H2 2017

Women Infertility – Dormant Projects, H2 2017

Women Infertility – Dormant Projects, H2 2017 (Contd..1), H2 2017

Women Infertility – Dormant Projects, H2 2017 (Contd..2), H2 2017

Women Infertility – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Women Infertility, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports